ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,0874
-0,19%
Bitcoin
66.696,49
-0,35%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Stealth BioTherapeutics Corporation (MITO)

  7. Stealth BioTherapeutics Corporation (MITO) News

MITO

Stealth BioTherapeutics (MITO)

Stealth BioTherapeutics Corporation
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:MITO
DatumZeitQuelleÜberschriftSymbolFirma
29/11/202200h41Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:MITOStealth BioTherapeutics Corporation
16/11/202222h23Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:MITOStealth BioTherapeutics Corporation
16/11/202222h22Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:MITOStealth BioTherapeutics Corporation
16/11/202222h20Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:MITOStealth BioTherapeutics Corporation
16/11/202222h19Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:MITOStealth BioTherapeutics Corporation
16/11/202222h16Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:MITOStealth BioTherapeutics Corporation
16/11/202222h14Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:MITOStealth BioTherapeutics Corporation
16/11/202222h10Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MITOStealth BioTherapeutics Corporation
16/11/202222h08Edgar (US Regulatory)Amended Statement of Ownership: Private Transaction (sc 13e3/a)NASDAQ:MITOStealth BioTherapeutics Corporation
16/11/202222h01PR Newswire (US)Stealth BioTherapeutics Corp Announces Completion of MergerNASDAQ:MITOStealth BioTherapeutics Corporation
01/11/202212h30PR Newswire (US)Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS)NASDAQ:MITOStealth BioTherapeutics Corporation
07/10/202222h01PR Newswire (US)Stealth BioTherapeutics Corp to Hold Extraordinary General Meeting of ShareholdersNASDAQ:MITOStealth BioTherapeutics Corporation
30/09/202223h01TipRanksStealth Biotherapeutics announces resignation of CFO Robert WeiskopfNASDAQ:MITOStealth BioTherapeutics Corporation
30/09/202223h00PR Newswire (US)Stealth BioTherapeutics Announces Departure of Chief Financial OfficerNASDAQ:MITOStealth BioTherapeutics Corporation
23/09/202223h21Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:MITOStealth BioTherapeutics Corporation
15/09/202222h45PR Newswire (US)Stealth BioTherapeutics to Participate in Upcoming Ultra-Rare Disease EventsNASDAQ:MITOStealth BioTherapeutics Corporation
19/08/202222h16Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MITOStealth BioTherapeutics Corporation
19/08/202215h50Edgar (US Regulatory)Statement of Ownership: Private Transaction (sc 13e3)NASDAQ:MITOStealth BioTherapeutics Corporation
01/08/202222h46Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:MITOStealth BioTherapeutics Corporation
01/08/202215h48Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MITOStealth BioTherapeutics Corporation
01/08/202214h30PR Newswire (US)Stealth BioTherapeutics Corp Enters Definitive Agreement for Going Private TransactionNASDAQ:MITOStealth BioTherapeutics Corporation
11/07/202223h21Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MITOStealth BioTherapeutics Corporation
11/07/202223h15PR Newswire (US)STEALTH BIOTHERAPEUTICS ANNOUNCES RECEIPT OF NON-COMPLIANCE NOTICE FROM NASDAQNASDAQ:MITOStealth BioTherapeutics Corporation
27/06/202222h50Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:MITOStealth BioTherapeutics Corporation
27/06/202216h25AllPennyStocks.comPremarket Indicating Higher Open For This BiotechNASDAQ:MITOStealth BioTherapeutics Corporation
27/06/202214h02Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MITOStealth BioTherapeutics Corporation
27/06/202213h30PR Newswire (US)Stealth BioTherapeutics Corp Announces Receipt of Preliminary Non-Binding ProposalNASDAQ:MITOStealth BioTherapeutics Corporation
16/06/202212h15TipRanksH.C. Wainwright Thinks Stealth Biotherapeutics’ Stock is Going to RecoverNASDAQ:MITOStealth BioTherapeutics Corporation
16/06/202212h05Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:MITOStealth BioTherapeutics Corporation
14/06/202213h25PR Newswire (US)Stealth BioTherapeutics Granted Pre-NDA Meeting for Elamipretide as a Potential Treatment for Barth SyndromeNASDAQ:MITOStealth BioTherapeutics Corporation
 Showing the most relevant articles for your search:NASDAQ:MITO

Kürzlich von Ihnen besucht

AMEX
SDVD
FT Vest SMID Rising Divi...
AMEX
UUUU.WS
Energy Fuels
EU
3474S
3474S
COIN
HETAETH
HetaChain Token
USOTC
BEOB
BEO Bancorp (PK)
HITB
QUICKUSDT
QuickSwap
BIT
UC4CTZ
Unicredit Bank
TSX
MINT
Manulife Multifactor Dev...
COIN
PAYTUSD
PayAccept
BIT
UC6MQY
Unicredit Bank
USOTC
BVVBY
Bureau Veritas (PK)
TSXV
LVH
BIT
UC915D
Unicredit Bank
BIT
UC7F5D
Unicredit Bank
BOV
ALPA4R
ALPARGATAS PN
EU
AFDFP
Agence Francaise de Deve...
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten